Search Within

Gary Ulaner

Formats
  1. Journal Article (95)
  2. Meeting Abstract (39)
  3. Miscellaneous (5)
  4. Review (4)
  5. Editorial (2)
  6. Book Whole (1)
  7. Guidelines (1)
Groups
  1. Molecular Imaging and Therapy Service (147)
  2. Radiology, Department of (147)
  3. Department of Medicine (75)
  4. Solid Tumor Oncology Division (60)
  5. GSK Faculty (59)
  6. Epidemiology and Biostatistics (46)

More Groups

People
  1. David Hyman (22)
  2. Christopher Riedl (21)
  3. Maxine Jochelson (21)
  4. Jason Lewis (20)
  5. Maura Dickler (19)
  6. Komal Jhaveri (18)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (2)
  4. 2022 (2)
  5. 2021 (12)
  6. 2020 (21)

More Years

Publications
  1. Journal of Nuclear Medicine (24)
  2. Clinical Nuclear Medicine (23)
  3. Journal of Clinical Oncology (16)
  4. Cancer Research (8)
  5. PET Clinics (7)
  6. European Journal of Nuclear Medicine and Molecular Imaging (6)

More Publications

Publishers
  1. Lippincott Williams & Wilkins (27)
  2. Society of Nuclear Medicine (24)
  3. American Society of Clinical Oncology (16)
  4. Elsevier Inc. (16)
  5. American Association for Cancer Research (12)
  6. Springer (8)

More Publishers

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • (18)F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials
    Journal Article

    Wang, Y.; Ayres, K. L.; Goldman, D. A.; Dickler, M. N.; Bardia, A.; Mayer, I. A.; Winer, E.; Fredrickson, J.; Arteaga, C. L.; Baselga, J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • (18)F–FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer
    Journal Article

    Ulaner, G. A.; Castillo, R.; Wills, J.; Gönen, M.; Goldman, D. A.
    European Journal of Nuclear Medicine and Molecular Imaging (2017)

    Fulltext@MSK | Save
  • Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer
    Journal Article

    Riedl, C. C.; Pinker, K.; Ulaner, G. A.; Ong, L. T.; Baltzer, P.; Jochelson, M. S.; McArthur, H. L.; Gönen, M.; Dickler, M.; Weber, W. A.
    European Journal of Nuclear Medicine and Molecular Imaging (2017)

    Fulltext@MSK | Save
  • Human epidermal growth factor receptor 2-targeted PET/single- photon emission computed tomography imaging of breast cancer: Noninvasive measurement of a biomarker integral to tumor treatment and prognosis
    Journal Article

    Henry, K. E.; Ulaner, G. A.; Lewis, J. S.
    PET Clinics (2017)

    Fulltext@MSK | Save
  • "Comment on Hatzoglou et al.: Dynamic contrastenhanced mri perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury" - Reply
    Journal Article

    Young, R. J.; Yang, T. J.; Hatzoglou, V.; Ulaner, G.; Omuro, A.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Transient osteoporosis of the hip on FDG PET/CT
    Journal Article

    Ulaner, G. A.; Sawan, P.
    Clinical Nuclear Medicine (2017)

    Fulltext@MSK | Save
  • FDG PET/CT assesses the risk of femoral pathological fractures in patients with metastatic breast cancer
    Journal Article

    Ulaner, G. A.; Zindman, A. M.; Zheng, J.; Kim, T. W. B.; Healey, J. H.
    Clinical Nuclear Medicine (2017)

    Fulltext@MSK | Save
  • Value of second-opinion review of outside institution PET-CT examinations
    Journal Article

    Ulaner, G. A.; Mannelli, L.; Dunphy, M.
    Nuclear Medicine Communications (2017)

    Fulltext@MSK | Save
  • Vemurafenib in patients with Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) harboring BRAF(V600) mutations: A cohort of the histology-independent VE-BASKET study
    Meeting Abstract

    Diamond, E. L.; Subbiah, V.; Lockhart, C.; Blay, J. Y.; Faris, J. E.; Puzanov, I.; Chau, I.; Raje, N. S.; Wolf, J. S.; Erinjeri, J.; more...
    Blood (2016)

    Fulltext@MSK | Save